APOE and Alzheimer disease: WMLs are common findings in AD (Richard et al., 2010), and Ferrari et al. (2018) reported that low-dose aspirin therapy slowed AD progression, especially among non-apolipoprotein E allele carriers via probable modulation of the WML burden on AD patients.